Physician profile
Joy Gandy
NPI 1457791642
$1,700.27
in general payments reported to CMS, 2019-2025
15 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $536 · 2023: $369 · 2024: $260 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $411.03 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.18 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $213.82 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $151.59 | 2023-2025 | Verquvo |
| Amgen INC. | $140.77 | 2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $116.91 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $99.50 | 2023 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $89.36 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $64.62 | 2023-2024 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $39.33 | 2021-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $24.63 | 2023 | Arcalyst |
| Abiomed | $24.60 | 2024 | Impella |
| Abbott Laboratories | $24.52 | 2024 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $17.53 | 2022 | |
| Scpharmaceuticals INC. | $14.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Gandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.